The adenosine monophosphate–activated protein kinase—vacuolar adenosine triphosphatase–pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells

Giusi Marrone, Francesco De Chiara, Katrin Böttcher, Ana Levi, Dipok Dhar, Lisa Longato, Giuseppe Mazza, Zhenzhen Zhang, Martina Marrali, Anabel Fernández‐Iglesias, Andrew Hall, Tu Vinh Luong, Benoit Viollet, Massimo Pinzani, Krista Rombouts – 17 April 2018 – Liver fibrosis and cirrhosis are characterized by activation of hepatic stellate cells (HSCs), which is associated with higher intracellular pH (pHi). The vacuolar H+ adenosine‐triphosphatase (v‐ATPase) multisubunit complex is a key regulator of pHi homeostasis.

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

Francesca Romana Ponziani, Sherrie Bhoori, Chiara Castelli, Lorenza Putignani, Licia Rivoltini, Federica Del Chierico, Maurizio Sanguinetti, Daniele Morelli, Francesco Paroni Sterbini, Valentina Petito, Sofia Reddel, Riccardo Calvani, Chiara Camisaschi, Anna Picca, Alessandra Tuccitto, Antonio Gasbarrini, Maurizio Pompili, Vincenzo Mazzaferro – 17 April 2018 – The gut–liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the third leading cause of hepatocellular carcinoma (HCC) worldwide.

Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu – 17 April 2018 – Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival benefits with sorafenib.

Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant

Jasmohan S. Bajaj, Genta Kakiyama, Tor Savidge, Hajime Takei, Zain A. Kassam, Andrew Fagan, Edith A. Gavis, William M. Pandak, Hiroshi Nittono, Phillip B. Hylemon, Prapaporn Boonma, Anthony Haag, Douglas M. Heuman, Michael Fuchs, Binu John, Masoumeh Sikaroodi, Patrick M. Gillevet – 17 April 2018 – Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis.

The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility

Lin Lee Wong, Holly F Fisher, Deborah D Stocken, Stephen Rice, Amardeep Khanna, Michael A Heneghan, Ye Htun Oo, George Mells, Stuart Kendrick, Jessica Katharine Dyson, David E. J. Jones, on behalf of the UK‐AIH Consortium – 17 April 2018 – Patient reporting suggests that the physical and psychological effects of autoimmune hepatitis (AIH) can be substantial. However, health‐related quality of life (HRQOL) in patients with AIH remains incompletely characterized, and health utility remains to be explored.

Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort

Domenico Tricò, Sonia Caprio, Giuseppina Rosaria Umano, Bridget Pierpont, Jessica Nouws, Alfonso Galderisi, Grace Kim, Mariana M. Mata, Nicola Santoro – 17 April 2018 – We conducted a prospective study in a large, multiethnic cohort of obese adolescents to characterize clinical and genetic features associated with pediatric nonalcoholic fatty liver (NAFL), the most common cause of chronic liver disease in youth. A total of 503 obese adolescents were enrolled, including 191 (38.0%) whites, 134 (26.6%) blacks, and 178 (35.4%) Hispanics.

Reply

Jacqueline G. O’Leary, K. Rajender Reddy, Florence Wong, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jasmohan S. Bajaj – 16 April 2018

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Manon Allaire, Pierre Nahon, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Ghassan Riachi, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Eri

Subscribe to